RestorGenex Corp  

(Public, OTCMKTS:RESX)   Watch this stock  
Find more results for B. Blech
+0.04 (3.96%)
Aug 28 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 1.05 - 1.05
52 week 0.90 - 4.50
Open 1.05
Vol / Avg. 200.00/13,763.00
Mkt cap 19.55M
P/E     -
Div/yield     -
EPS -0.83
Shares 18.61M
Beta 0.48
Inst. own 0%
Nov 10, 2015
Q3 2015 RestorGenex Corp Earnings Release (Estimated) Add to calendar
Sep 9, 2015
RestorGenex Corp at Rodman & Renshaw Global Investment Conference - 4:15PM EDT - Add to calendar
Aug 12, 2015
Q2 2015 RestorGenex Corp Earnings Release
Jun 2, 2015
RestorGenex Corp at LD Micro Invitational Conference

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -41.75% -46.96%
Return on average equity -47.48% -64.33%
Employees 8 -
CDP Score - -


2150 E Lake Cook Rd Ste 750
BUFFALO GROVE, IL 60089-8227
United States - Map
+1-847-7778092 (Phone)
+1-213-9956337 (Fax)

Website links


RestorGenex Corporation is a specialty biopharmaceutical company focused on developing products for ophthalmology, oncology and dermatology. The Company's lead product is a PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The Company's pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. The Company's product candidates include RES-529, which is offered in the area of ophthalmology and oncology for Age-Related Macular Degeneration (AMD) and Glioblastoma Multiforme (GBM) conditions, respectively, and RES-440 for Acnes in the area of Dermatology. The Company has developed small molecule zinc-finger transcription factor inhibitors/activators.

Officers and directors

Sol J. Barer Ph.D. Chairman of the Board
Age: 68
Stephen M. Simes Chief Executive Officer, Director
Age: 63
Isaac Blech Vice Chairman of the Board
Age: 65
Phillip B. Donenberg Chief Financial Officer, Secretary
Age: 54
Mark Weinberg M.D. Senior Vice President - Clinical Development
David Sherris M.D., Ph.D. Chief Scientific Officer, President - Paloma/VasculoMedics Divisions, Director
Age: 61
Rex Bright Director
Age: 74
Nelson K. Stacks Director
Age: 44